What we do Remus Pharmaceuticals Ltd markets and distributes a wide range of pharmaceutical formulations including capsules, tablets, and injectables, focusing on contract manufacturing and API trading globally. |
Founded in 2,015 |
Market share Expanding global footprint with presence in over 40 countries; rapidly growing in Latin America, particularly Bolivia. |
Problem solved Provides accessible, approved pharmaceutical formulations and APIs to global markets, aiding healthcare delivery through contract manufacturing and technical consultancy. |
Top clients or who we serve Serves global distributors, hospitals, pharmacies, primarily in export markets including Latin America; B2B focus with some healthcare institutions. |
Key management Mr. Arpit Deepakkumar Shah (Managing Director), Mr. Swapnil Jatinbhai Shah (Chairman) |
Our journey and innovations Founded in 2015; IPO in 2023; expanded via acquisitions and subsidiaries in Latin America and USA; launched multiple pharmacies and hospital partnerships. |
Where we operate India (domestic operations), Latin America, USA, Guatemala, Bolivia; over 40 countries worldwide. |
Top products or what we offer Pharmaceutical formulations including ACE inhibitors, antibiotics, antidiabetics, antifungals; API trading; technical pharmaceutical consultancy. |
Top brands - |
Raw materials needed APIs and excipients sourced for pharmaceutical formulations. |
Raw materials supplier - |
Recurring vs cyclical contribution Primarily recurring revenue from contract manufacturing and pharmaceutical distribution. |
Our industry position Emerging player with strong growth and expanding international presence in pharma formulations and API markets. |
Financial highlights Consolidated revenue ₹620 crores with 58% profit growth to ₹38 crores in FY 2024-25; standalone profit ₹19.9 crores. |
Geographical revenue split Domestic revenue ₹344 crores; export revenue ₹276 crores in FY 2024-25. |
Order book - |
Whats driving growth Strategic acquisitions, portfolio expansion, geographical diversification, and increasing healthcare demand in Latin America. |
Our future plans Growing product launches in Latin America, enlarging subsidiary operations, enhancing marketing networks, and expanding contract manufacturing. |
Our green promise - |
Our people and values 68 employees with focus on performance management, inclusion, and employee wellbeing. |
Key challenges ahead Managing international regulatory compliance, competitive pharmaceutical markets, and supply chain risks. |
Interesting facts Successfully listed on NSE EMERGE in 2023; launched over 10 products across Bolivian hospital and pharmacy chains in 2025. |
Risks and strategy Risk mitigation via diversified manufacturing contracts and geography; strategy includes innovation and careful regulatory adherence. |
